MTHRF:OTO-M3 Inc (USD)

COMMON STOCK | Health Information Services | OTC Pink

Last Closing

USD 10.03

Change

0.00 (0.00)%

Market Cap

USD 7.95B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

M3, Inc. supplies medical information services for doctors through Internet. It also supports marketing of pharmaceutical companies and medical equipment manufacturers.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
PMCUF Pro Medicus Limited

N/A

USD 8.70B
MTHRY M3 Inc

N/A

USD 7.06B
PANHF Ping An Healthcare and Technol..

N/A

USD 1.64B
CRWRF Craneware plc

N/A

USD 1.09B
SMSZF SMS Co. Ltd

N/A

USD 1.09B
SUSRF Surgical Science Sweden AB (pu..

N/A

USD 0.71B
RSLBF RaySearch Laboratories AB (pub..

N/A

USD 0.44B
VHIBF Vitalhub Corp

N/A

USD 0.27B
KSIOF kneat.com inc.

N/A

USD 0.27B
AMJT AMJ Global Technology

N/A

USD 0.15B

ETFs Containing MTHRF

FJP:PA 2.33 % 0.00 %

N/A

N/A
EXX7:F iShares Nikkei 225 UCITS .. 0.00 % 0.00 %

N/A

USD 27.04B
SXRZ:F iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 55.70B
XDJE:F Xtrackers - Nikkei 225 UC.. 0.00 % 0.00 %

N/A

N/A
XDJP:F Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

N/A

N/A
EXX7:XETRA iShares Nikkei 225 UCITS .. 0.00 % 0.00 %

N/A

USD 28.25B
SXRZ:XETRA iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 58.15B
XDJE:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

N/A

USD 0.03B
XDJP:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

N/A

USD 157.79B
1329:TSE iShares Core Nikkei 225 E.. 0.00 % 0.00 %

N/A

USD 1,529.93B
1330:TSE Nikko Nikkei 225 Listed 0.00 % 0.00 %

N/A

USD 5,423.56B
1578:TSE Listed Index Fund Nikkei .. 0.00 % 0.00 %

N/A

USD 12.13B
1652:TSE Daiwa MSCI Japan Empoweri.. 0.00 % 0.00 %

N/A

USD 0.70B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.50% 35% F 17% F
Dividend Return 1.04% 50% F 22% F
Total Return -31.46% 34% F 17% F
Trailing 12 Months  
Capital Gain -57.50% 38% F 18% F
Dividend Return 0.65% 50% F 8% B-
Total Return -56.85% 40% F 19% F
Trailing 5 Years  
Capital Gain -45.43% 63% D 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.43% 63% D 38% F
Average Annual (5 Year Horizon)  
Capital Gain 23.18% 71% C- 68% D+
Dividend Return 30.46% 73% C 69% C-
Total Return 7.28% 71% C- 79% B-
Risk Return Profile  
Volatility (Standard Deviation) 97.21% 47% F 33% F
Risk Adjusted Return 31.33% 85% B 67% D+
Market Capitalization 7.95B 100% F 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.